Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt small index

Muscular Dystrophy: early-phase trial registry

10 of 12 indexed Muscular Dystrophy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 10 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Muscular Dystrophy: 12 US clinical trials tracked, 10 recruiting.

Muscular Dystrophy is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Neurological Disorders and Stroke (NINDS), running 2 of these trials.

Enrollment posture brief

Registry condition muscular-dystrophy

OPEN 10 | RECR 83% | LATE 0 | EARLY 2 | RANK #1429 | SPON 2

Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)

Muscular Dystrophy (this)83%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Muscular Dystrophy

Muscular Dystrophy lists 10 open slots (83% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Muscular Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Muscular Dystrophy is recruiting above its size-band peers.

    10 of 12 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Muscular Dystrophy research.

    National Institute of Neurological Disorders and Stroke (NINDS) accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Muscular Dystrophy enrolment sits around 190 participants.

    Median target enrolment is 190 among the 12 trials that report a genuine target (sentinel values excluded). 5 of those (41.7%) plan for fewer than 100 participants.

  4. Muscular Dystrophy splits between interventional and observational designs.

    5 interventional and 7 observational studies make up this index (41.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Open and recent trials

12 total, page 1 of 1

RECRUITING 3,500 participants

Study of Inherited Neurological Disorders

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00004568

RECRUITING 3,000 participants

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

University of Rochester

NCT00082108

RECRUITING 2,000 participants

Genetics of Cardiovascular and Neuromuscular Disease

University of Chicago

NCT00138931

RECRUITING 190 participants

Clinical Trial Readiness for the Dystroglycanopathies

Katherine Mathews

NCT00313677

RECRUITING 150 participants

Investigational Use of Neuromuscular Ultrasound

National Institute of Neurological Disorders and Stroke (NINDS)

NCT05237973

RECRUITING Phase 2 50 participants

Vasodilator and Exercise Study for DMD (VASO-REx)

University of Florida

NCT06290713

RECRUITING NA 44 participants

Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders

National Institutes of Health Clinical Center (CC)

NCT05726591

RECRUITING NA 36 participants

Nomad P-KAFO Study

Shirley Ryan AbilityLab

NCT05644522

RECRUITING NA 27 participants

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

Leigh R. Hochberg, MD, PhD.

NCT00912041

RECRUITING Phase 1 10 participants

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

AskBio

NCT05230459

COMPLETED 448 participants

Arrhythmias in Myotonic Muscular Dystrophy

Indiana University School of Medicine

NCT00622453

COMPLETED 230 participants

Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

Nemours Children's Clinic

NCT02532244

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Muscular Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

sample collection Other
1 trials
Placement of the BrainGate2 sensor(s) into the motor-related cortex Device
1 trials
Tadalafil Drug
1 trials
Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH) Device
1 trials
Screening Other
1 trials
Blood draw (genetic testing) Procedure
1 trials
AB-1003 dose level 2 Genetic
1 trials
AB-1003 dose level 1 Genetic
1 trials

US sites by state

Facility locations filed on Muscular Dystrophy trials. A trial with sites in several states counts in each.

Maryland 4 trials
Illinois 2 trials
Iowa 2 trials
Florida 2 trials
California 2 trials
Washington 1 trials
Virginia 1 trials
Rhode Island 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Muscular Dystrophy page

12 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Muscular Dystrophy condition card totals 12 registered trials; most-linked intervention sample collection; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.